| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 09 Nov 2026 | 10-Q |
| 09 Nov 2026 |
8-K: Results of Operations and Financial Condition
EVERY BREAKTHROUGH BEGINS WITH BELIEF November 2026 Corporate Presentation |
| 07 Oct 2026 | SCHEDULE 13G |
| 06 Oct 2026 | SCHEDULE 13G |
| 02 Oct 2026 |
Form 4: McMinn Rachel, Director
Received 756 shares by exercise or conversion ($19.1K) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 11 Aug 2026 | 10-Q |
| 11 Aug 2026 |
8-K: Results of Operations and Financial Condition
EVERY BREAKTHROUGH BEGINS WITH BELIEF August 2026 Corporate Presentation |
| 07 Jul 2026 |
Form 4: Cvijic Christine Mikail, Director
Sold 600 shares ($21.6K) · Sold 4,200 shares ($152K) |
| 02 Jul 2026 |
Form 4: Cvijic Christine Mikail, Director
Sold 739 shares ($25.2K) · Sold 4,061 shares ($141K) |
| 02 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Pre-Funded Warrants to purchase up to 666,666 shares of Common Stock |
| 02 Jul 2026 | 424B5 |
| 30 Jun 2026 | 424B5 |
| 29 Jun 2026 |
8-K: Regulation FD Disclosure; Other Events
Restarting Development in Rett Syndrome NGN-401 for Rett Syndrome Phase 1/2 Update June 29, 2026 |
| 16 Jun 2026 |
Form 4/A: Woods Keith, Director
Granted 15,400 Stock Option (Right to Buy) |
Loading...